



## Infectious Diseases Clinical Research Consortium

### PUBLICATIONS

Stanley AM, Aksyuk AA, Wilkins D, Green JA, Lan D, Shoemaker K, Tieu HV, Sobieszczyk ME, Falsey AR, Kelly EJ. Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity. *Front Immunol*. 2024 May 17;15:1401728.

<https://doi.org/10.3389/fimmu.2024.1401728> eCollection 2024. PMID: 38827749; PMCID: PMC11143795

Paules CI, Wang J, Tomashek KM, Bonnett T, Singh K, Marconi VC, Davey RT Jr, Lye DC, Dodd LE, Yang OO, Benson CA, Deye GA, Doernberg SB, Hynes NA, Grossberg R, Wolfe CR, Nayak SU, Short WR, Voell J, Potter GE, Rapaka RR. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. *Ann Intern Med*. 2024 Mar;177(3):343-352. <https://doi.org/10.7326/M23-2593> Epub 2024 Feb 27. PMID: 38408357

Kalkeri R, Zhu M, Cloney-Clark S, Plested JS, Parekh A, Gorinson D, Cai R, Mahato S, Ramanathan P, Aurelia LC, Selva KJ, Marchese AM, Fries L, Chung AW, Dunkle LM. Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines. *J Infect*. 2024 Mar;88(3):106119.

<https://doi.org/10.1016/j.jinf.2024.106119> Epub 2024 Feb 13. PMID: 38360356

Cardemil CV, Cao Y, Posavad CM, Badell ML, Bunge K, Mulligan MJ, Parameswaran L, Olson-Chen C, Novak RM, Brady RC, DeFranco E, Gerber JS, Pasetti M, Shriver M, Coler R, Berube B, Suthar MS, Moreno A, Gao F, Richardson BA, Beigi R, Brown E, Neuzil KM, Munoz FM; MOMI-Vax Study Group. Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants. *Pediatrics*. 2024 Mar 1;153(3):e2023064252.

<https://doi.org/10.1542/peds.2023-064252> PMID: 38332733; PMCID: PMC10904887

Paulsen GC, Frenck R Jr, Tomashek KM, Alarcon RM, Hensel E, Lowe A, Brocato RL, Kwilas SA, Josleyn MD, Hooper JW. Safety and Immunogenicity of an Andes Virus DNA Vaccine by Needle-Free Injection: A Randomized, Controlled Phase 1 Study. *J Infect Dis*. 2024 Jan 12;229(1):30-38. <https://doi.org/10.1093/infdis/jiad235> PMID: 37380156; PMCID: PMC10786244

Xu M, O'Brien MP, Hooper AT, Forleo-Neto E, Isa F, Hou P, Chan KC, Cohen MS, Marovich MA, Hamilton JD, Hirshberg B, Herman GA, Musser BJ. Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection. *Open Forum Infect Dis*. 2023 Dec 2;10(12):ofad598.

<https://doi.org/10.1093/ofid/ofad598> eCollection 2023 Dec. PMID: 38111750; PMCID: PMC10727195

Dayan GH, Roupheal N, Walsh SR, Chen A, Grunenber N, Allen M, Antony J, Asante KP, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Dobrianskyi D, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kibuuka H, Koutsoukos M, Masotti R, Michael NL, Neuzil KM, Reynales H, Robb ML, Villagómez Martínez SM, Sawe F, Schuerman L, Tong T, Treanor J, Wartel TA, Diazgranados CA, Chiczy RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 Study Team. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. *Lancet Respir Med*. 2023 Nov;11(11):975-990. [https://doi.org/10.1016/S2213-2600\(23\)00263-1](https://doi.org/10.1016/S2213-2600(23)00263-1) Epub 2023 Sep 13. PMID: 37716365; PMCID: PMC10872639

Dayan GH, Roupael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kaali S, Koutsoukos M, Masotti R, Michael NL, Neuzil KM, Reynales H, Robb ML, Uchiyama A, Sawe F, Schuerman L, Shrestha R, Tong T, Treanor J, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 study team. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study. *EClinicalMedicine*. 2023 Sep 12;64:102168.

<https://doi.org/10.1016/j.eclinm.2023.102168> eCollection 2023 Oct. PMID: 37936652; PMCID: PMC10626161

Branche AR, Roupael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Malkin E, Bethony JM, Walsh EE, Graciaa DS, Samaha H, Sherman AC, Walsh SR, Abate G, Oikonomopoulou Z, El Sahly HM, Martin TCS, Kamidani S, Smith MJ, Ladner BG, Porterfield L, Dunstan M, Wald A, Davis T, Atmar RL, Mulligan MJ, Lyke KE, Posavad CM, Meagher MA, Stephens DS, Neuzil KM, Abebe K, Hill H, Albert J, Telu K, Mu J, Lewis TC, Giebeig LA, Eaton A, Netzl A, Wilks SH, Türelı S, Makhene M, Crandon S, Montefiori DC, Makowski M, Smith DJ, Nayak SU, Roberts PC, Beigel JH; COVAIL Study Group. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. *Nat Med*. 2023 Sep;29(9):2334-2346.

<https://doi.org/10.1038/s41591-023-02503-4> Epub 2023 Aug 28. PMID: 37640860; PMCID: PMC10504073

Mackman RL, Kalla RV, Babusis D, Pitts J, Barrett KT, Chun K, Du Pont V, Rodriguez L, Moshiri J, Xu Y, Lee M, Lee G, Bleier B, Nguyen AQ, O'Keefe BM, Ambrosi A, Cook M, Yu J, Dempah KE, Bunyan E, Riola NC, Lu X, Liu R, Davie A, Hsiang TY, Dearing J, Vermillion M, Gale M Jr, Niedziela-Majka A, Feng JY, Hedskog C, Bilello JP, Subramanian R, Cihlar T. Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys. *J Med Chem*. 2023 Sep 14;66(17):11701-11717. <https://doi.org/10.1021/acs.jmedchem.3c00750> Epub 2023 Aug 19. PMID: 37596939

Turley CB, Tables L, Fuller T, Sanders LJ, Scott H, Moodley A, Woodward Davis A, Leav B, Miller J, Schoemaker K, Vandebosch A, Sadoff J, Woo W, Cho I, Dunkle LM, Li S, van der Laan L, Gilbert PB, Follmann D, Jaynes H, Kublin JG, Baden LR, Goepfert P, Kotloff K, Gay CL, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y, Neuzil KM, Corey L, Grinsztejn B, Gray G, Roupael N, Luedtke A; COVID-19 Prevention Network CoVPN. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials. *Vaccine*. 2023 Jul 25;41(33):4899-4906. <https://doi.org/10.1016/j.vaccine.2023.06.066> Epub 2023 Jun 23. PMID: 37385888; PMCID: PMC10288314

Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge KE, Mulligan MJ, Parameswaran L, Kelly CW, Olson-Chen C, Novak RM, Brady RC, Pasetti MF, Defranco EA, Gerber JS, Shriver MC, Suthar MS, Coler RN, Berube BJ, Kim SH, Piper JM, Miller AM, Cardemil CV, Neuzil KM, Beigi RH; DMID 21-0004 Study Group. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. *Vaccine*. 2023 Aug 14;41(36):5296-5303.

<https://doi.org/10.1016/j.vaccine.2023.06.032> Epub 2023 Jun 13. PMID: 37451878; PMCID: PMC10261713

Hedskog C, Rodriguez L, Roychoudhury P, Huang ML, Jerome KR, Hao L, Ireton RC, Li J, Perry JK, Han D, Camus G, Greninger AL, Gale M, Porter DP. Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1). *J Infect Dis*. 2023 Jul 19;jjad270. <https://doi.org/10.1093/infdis/jjad270> Online ahead of print. PMID: 37466213; PMCID:

Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, Johnston C, El Sahly HM, Edupuganti S, Mulligan MJ, Jackson LA, Rupp RE, Rostad CA, Coler RN, Bäcker M, Kottkamp AC, Babu TM, Dobrzynski D, Martin JM, Brady RC, Frenck RW Jr, Rajakumar K, Kotloff K, Roupael N, Szydlo D, PaulChoudhury R, Archer JI, Crandon S, Ingersoll B, Eaton A, Brown ER, McElrath MJ, Neuzil KM, Stephens DS, Post DJ, Lin BC, Serebryanny L, Beigel JH, Montefiori DC, Roberts PC; DMID 21-0012 Study Group. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. *NPJ Vaccines*. 2023 Jul 11;8(1):98.

<https://doi.org/10.1038/s41541-023-00693-z> PMID: 37433788; PMCID: PMC10336079

Savan R, Gale M Jr. Innate immunity and interferon in SARS-CoV-2 infection outcome. *Immunity*. 2023 Jul 11;56(7):1443-1450. <https://doi.org/10.1016/j.immuni.2023.06.018> PMID: 37437537; PMCID: PMC10361255

Follmann D, O'Brien MP, Fintzi J, Fay MP, Montefiori D, Mateja A, Herman GA, Hooper AT, Turner KC, Chan KC, Forleo-Neto E, Isa F, Baden LR, El Sahly HM, Janes H, Doria-Rose N, Miller J, Zhou H, Dang W, Benkeser D, Fong Y, Gilbert PB, Marovich M, Cohen MS. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. *Nat Commun*. 2023 Jun 17;14(1):3605. <https://doi.org/10.1038/s41467-023-39292-w> PMID: 37330602; PMCID: PMC10276829

Bannick MS, Gao F, Brown ER, Janes HE. Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2. *Am J Epidemiol*. 2023 Jun 2;192(6):1016-1028. <https://doi.org/10.1093/aje/kwad046> PMID: 36883907

Ortega-Villa AM, Hynes NA, Levine CB, Yang K, Wiley Z, Jilg N, Wang J, Whitaker JA, Colombo CJ, Nayak SU, Kim HJ, Iovine NM, Ince D, Cohen SH, Langer AJ, Wortham JM, Atmar RL, El Sahly HM, Jain MK, Mehta AK, Wolfe CR, Gomez CA, Beresnev T, Mularski RA, Paules CI, Kalil AC, Branche AR, Luetkemeyer A, Zingman BS, Voell J, Whitaker M, Harkins MS, Davey RT Jr, Grossberg R, George SL, Tapson V, Short WR, Ghazaryan V, Benson CA, Dodd LE, Sweeney DA, Tomashek KM. Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case. *Open Forum Infect Dis*. 2023 May 27;10(6):ofad290. <https://doi.org/10.1093/ofid/ofad290> eCollection 2023 Jun. PMID: 37383244; PMCID: PMC10296069

Brown ER, O'Brien MP, Snow B, Isa F, Forleo-Neto E, Chan KC, Hou P, Cohen MS, Herman G, Barnabas RV. A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2. *Open Forum Infect Dis*. 2023 May 23;10(7):ofad271. <https://doi.org/10.1093/ofid/ofad271> eCollection 2023 Jul. PMID: 37416758; PMCID: PMC10319621

Marchese AM, Zhou X, Kinol J, Underwood E, Woo W, McGarry A, Beyhaghi H, Áñez G, Toback S, Dunkle LM. NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial. *Vaccine*. 2023 May 22;41(22):3461-3466. <https://doi.org/10.1016/j.vaccine.2023.04.054> Epub 2023 Apr 29. PMID: 37127523; PMCID: PMC10148668

Áñez G, Kotloff KL, Gay CL, Nelson J, Dunbar H, Cloney-Clark S, McGarry A, Woo W, Cho I, Pledsted JS, Glenn GM, Dunkle LM. Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico. *medRxiv*. 2023 May 11:2023.05.08.23289670. <https://doi.org/10.1101/2023.05.08.23289670> Preprint. PMID: 37214968; PMCID: PMC10197803

Benkeser D, Montefiori DC, McDermott AB, Fong Y, Janes HE, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Kenny A, Carone M, Williamson BD, Garver J, Altonen E, Rudge T, Huynh C, Miller J, El Sahly HM, Baden LR, Frey S, Malkin E, Spector SA, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA, Gilbert PB; Immune Assays; Moderna Inc.; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE); United States Government (USG)/CoVPN Biostatistics Teams. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. *Sci Transl Med*. 2023 Apr 19;15(692):eade9078. <https://doi.org/10.1126/scitranslmed.ade9078> Epub 2023 Apr 19. PMID: 37075127; PMCID: PMC10243212

Áñez G, Dunkle LM, Gay CL, Kotloff KL, Adelglass JM, Essink B, Campbell JD, Cloney-Clark S, Zhu M, Pledsted JS, Roychoudhury P, Greninger AL, Patel N, McGarry A, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301–Pediatric Expansion Study Group. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial. *JAMA Netw Open*. 2023 Apr 3;6(4):e239135. <https://doi.org/10.1001/jamanetworkopen.2023.9135> PMID: 37099299

Branche AR, Roupael NG, Losada C, Baden LR, Anderson EJ, Luetkemeyer AF, Diemert DJ, Winokur PL, Presti RM, Kottkamp AC, Falsey AR, Frey SE, Rupp R, Bäcker M, Novak RM, Walter EB, Jackson LA, Little SJ, Immergluck LC, Mahgoub SM, Whitaker JA, Babu TM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH. Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial. *Clin Infect Dis*. 2023 Apr 10:ciad209. <https://doi.org/10.1093/cid/ciad209> Epub ahead of print. PMID: 37036397

Benkeser D, Fong Y, Janes HE, Kelly EJ, Hirsch I, Sproule S, Stanley AM, Maaske J, Villafana T, Houchens CR, Martins K, Jayashankar L, Castellino F, Ayala V, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Carpp LN, Randhawa AK, Andrasik MP, Kublin JG, Isaacs MB, Makhene M, Tong T, Robb ML, Corey L, Neuzil KM, Follmann D, Hoffman C, Falsey AR, Sobieszczyk M, Koup RA, Donis RO, Gilbert PB; AstraZeneca AZD1222 Clinical Study Group; Immune Assays Team; United States Government (USG)/CoVPN Biostatistics Team. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. *NPJ Vaccines*. 2023 Mar 11;8(1):36. <https://doi.org/10.1038/s41541-023-00630-0> PMID: 36899062; PMCID: PMC10005913

Follmann D, Janes HE, Chu E, Jayashankar L, Petropoulos CJ, Serebryanny L, Carroll R, Jean-Baptiste N, Narpala S, Lin BC, McDermott A, Novak RM, Graciaa DS, Rolsma S, Magaret CA, Doria-Rose N, Corey L, Neuzil KM, Pajon R, Miller JM, Donis RO, Koup RA, Baden LR, El Sahly HM. Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. *Open Forum Infect Dis*. 2023 Feb 13;10(3):ofad069. <https://doi.org/10.1093/ofid/ofad069> eCollection 2023 Mar. PMID: 36895286; PMCID: PMC9991588

Fong Y, Huang Y, Benkeser D, Carpp LN, Áñez G, Woo W, McGarry A, Dunkle LM, Cho I, Houchens CR, Martins K, Jayashankar L, Castellino F, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Randhawa AK, Andrasik MP, Kublin JG, Hutter J, Keshtkar-Jahromi M, Beresnev TH, Corey L, Neuzil KM, Follmann D, Ake JA, Gay CL, Kotloff KL, Koup RA, Donis RO, Gilbert PB; Immune Assays Team; Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team; United States Government (USG)/CoVPN Biostatistics Team. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. *Nat Commun*. 2023 Jan 19;14(1):331. <https://doi.org/10.1038/s41467-022-35768-3> PMID: 36658109; PMCID: PMC9851580

Aksyuk AA, Bansal H, Wilkins D, Stanley AM, Sproule S, Maaske J, Sanikommui S, Hartman WR, Sobieszczyk ME, Falsey AR, Kelly EJ. AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection. *EJ Cell Rep Med*. 2023 Jan 17;4(1):100882. <https://doi.org/10.1016/j.xcrm.2022.100882> PMID: 36610390; PMCID: PMC9750884

Dayan GH, Roupael N, Walsh SR, Chen A, Grunenber N, Allen M, Antony J, Asante KP, Suresh Bhat A, Beresnev T, Bonaparte MI, Angeles Ceregido M, Dobrianskyi D, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Jin Kee J, Kibuuka H, Koutsoukos M, Masotti R, Michael NL, Reynales H, Robb ML, Villagómez Martínez SM, Sawe F, Schuerman L, Tong T, Treanor J, Wartel TA, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 study team. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine. *medRxiv*. 2023 Jan 13;2022.12.05.22282933. <https://doi.org/10.1101/2022.12.05.22282933> PMID: 36523415; PMCID: PMC9753788

Siangphoe U, Baden LR, El Sahly HM, Essink B, Ali K, Berman G, Tomassini JE, Deng W, Pajon R, McPhee R, Dixit A, Das R, Miller JM, Zhou H; COVE and TeenCOVE Study Groups. Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. *Clin Infect Dis*. 2023 Jan 13;76(2):271-280. <https://doi.org/10.1093/cid/ciac780> PMID: 36130187; PMCID: PMC10202429

Maaske J, Sproule S, Falsey AR, Sobieszczyk ME, Luetkemeyer AF, Paulsen GC, Riddler SA, Robb ML, Rolle CP, Sha BE, Tong T, Ahani B, Akxyuk AA, Bansal H, Egan T, Jepson B, Padilla M, Patel N, Shoemaker K, Stanley AM, Swanson PA, Wilkins D, Villafana T, Green JA, Kelly EJ. Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated. *Front Immunol*. 2023 Jan 13;13:1062067. <https://doi.org/10.3389/fimmu.2022.1062067> eCollection 2022. PMID: 36713413; PMCID: PMC9881590

Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Roupheal N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, Neuzil K, Corey L, Kublin JG; COVID-19 Prevention Network. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. *JAMA Netw Open*. 2023 Jan 3;6(1):e2251974. <https://doi.org/10.1001/jamanetworkopen.2022.51974> PMID: 36689221

Potter GE, Bonnett T, Rubenstein K, Lindholm DA, Rapaka RR, Doernberg SB, Lye DC, Mularski RA, Hynes NA, Kline S, Paules CI, Wolfe CR, Frank MG, Roupheal NG, Deye GA, Sweeney DA, Colombo RE, Davey RT Jr, Mehta AK, Whitaker JA, Castro JG, Amin AN, Colombo CJ, Levine CB, Jain MK, Maves RC, Marconi VC, Grossberg R, Hozayen S, Burgess TH, Atmar RL, Ganesan A, Gomez CA, Benson CA, Lopez de Castilla D, Ahuja N, George SL, Nayak SU, Cohen SH, Lalani T, Short WR, Erdmann N, Tomashek KM, Tebas P. Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. *Ann Intern Med*. 2022 Dec;175(12):1716-1727. <https://doi.org/10.7326/M22-2116> Epub 2022 Nov 29. PMID: 36442063; PMCID: PMC9709721

El Sahly HM, Baden LR, Essink B, Montefiori D, McDermont A, Rupp R, Lewis M, Swaminathan S, Griffin C, Fragoso V, Miller VE, Girard B, Paila YD, Deng W, Tomassini JE, Paris R, Schödel F, Das R, August A, Leav B, Miller JM, Zhou H, Pajon R; Coronavirus Efficacy (COVE) Study Group. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. *J Infect Dis*. 2022 Nov 11;226(10):1731-1742. <https://doi.org/10.1093/infdis/jiac188> PMID: 35535503; PMCID: PMC9213865

Anderson EJ, Creech CB, Berthaud V, Piramzadian A, Johnson KA, Zervos M, Garner F, Griffin C, Palanpurwala K, Turner M, Gerber J, Bennett RL, Ali K, Ampajwala M, Berman G, Nayak J, Chronis C, Rizzardi B, Muller WJ, Smith CA, Fuchs G, Hsia D, Tomassini JE, DeLucia D, Reuter C, Kuter B, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, McPhee R, Pajon R, Aunins A, Das R, Miller JM, Schnyder Ghamloush S; KidCOVE Study Group. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. *N Engl J Med*. 2022 Nov 3;387(18):1673-1687. <https://doi.org/10.1056/NEJMoa2209367> Epub 2022 Oct 19. PMID: 36260859; PMCID: PMC9634866

Herman GA, O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Musser BJ, Davis JD, Turner KC, Mahmood A, Hooper AT, Hamilton JD, Parrino J, Subramaniam D, Baum A, Kyratsous CA, DiCioccio AT, Stahl N, Braunstein N, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis*. 2022 Oct;22(10):1444-1454. [https://doi.org/10.1016/S1473-3099\(22\)00416-9](https://doi.org/10.1016/S1473-3099(22)00416-9) Epub 2022 Jul 5. PMID: 35803290; PMCID: PMC9255947

Scherer EM, Backer M, Carvajal K, Danziger-Isakov L, Frey S, Howard LM, Scaggs Huang F, Kottkamp AC, Reid T, Rodriguez-Barradas MC, Stankiewicz Karita HC, Teoh Z, Wald A, Whitaker J, Wiley Z, Ofotokun I, Edwards KM; Infectious Diseases Clinical Research Consortium (IDCRC) Mentorship Program Writing Group. The Coronavirus Disease 2019 Pandemic Unmasked the Challenges Faced by Early-Stage Faculty in Infectious Diseases: A Call to Action. *Clin Infect Dis*. 2022 Sep 22;76(4):753-759. <https://doi.org/10.1093/cid/ciac779> PMID: 36131321; PMCID: PMC9494497

Le Gars M, Sadoff J, Struyf F, Heerwegh D, Truyers C, Hendriks J, Gray G, Grinsztejn B, Goepfert PA, Schuitemaker H, Douoguih M. Impact of Preexisting Anti-Ad26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S COVID-19 Vaccine. *The Journal of Infectious Diseases*. 2022 Sep 22; jiac142. <https://doi.org/10.1093/infdis/jiac142> PMID: 35429381; PMCID: PMC9047246

Sobieszczyk ME, Maaske J, Falsey AR, Sproule S, Robb ML, Frenck RW Jr, Tieu HV, Mayer KH, Corey L, Neuzil KM, Tong T, Brewinski Isaacs M, Janes H, Bansal H, Edwards LM, Green JA, Kelly EJ, Shoemaker K, Takas T, White T, Bhuyan P, Villafana T, Hirsch AI; AstraZeneca AZD1222 Clinical Study Group. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. *J Clin Invest*. 2022 Sep 15;132(18):e160565. <https://doi.org/10.1172/JCI160565> PMID: 36106642; PMCID: PMC9479753

Deming ME, Dong TQ, Agrawal V, Mills MG, Huang MLW, Greninger AL, Jerome KR, Wener MH, Paasche-Orlow MK, Kissinger P, Luk A, Hoffman RM, Stewart J, Kottkamp AC, Bershteyn A, Chu HY, Stankiewicz Karita HC, Johnston CM, Wald A, Barnabas R, Brown ER, Neuzil KM. Detection and Kinetics of Subgenomic Severe Acute Respiratory Syndrome Coronavirus 2 RNA Viral Load in Longitudinal Diagnostic RNA-Positive Samples. *J Infect Dis*. 2022 Sep 13;226(5):788-796. <https://doi.org/10.1093/infdis/jiac048> PMID: 35150571; PMCID: PMC8903395

Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM, Miller JM, El Sahly HM, Baden LR. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. *Ann Intern Med*. 2022 Sep;175(9):1258-1265. <https://doi.org/10.7326/M22-1300> Epub 2022 Jul 5. PMID: 35785530; PMCID: PMC9258784

Wolfe CR, Tomashek KM, Patterson TF, Gomez CA, Marconi VC, Jain MK, Yang OO, Paules CI, Palacios GMR, Grossberg R, Harkins MS, Mularski RA, Erdmann N, Sandkovsky U, Almasri E, Pineda JR, Dretler AW, de Castilla DL, Branche AR, Park PK, Mehta AK, Short WR, McLellan SLF, Kline S, Iovine NM, El Sahly HM, Doernberg SB, Oh MD, Huprikar N, Hohmann E, Kelley CF, Holodniy M, Kim ES, Sweeney DA, Finberg RW, Grimes KA, Maves RC, Ko ER, Engemann JJ, Taylor BS, Ponce PO, Larson L, Melendez DP, Seibert AM, Roupheal NG, Strebe J, Clark JL, Julian KG, de Leon AP, Cardoso A, de Bono S, Atmar RL, Ganesan A, Ferreira JL, Green M, Makowski M, Bonnett T, Beresnev T, Ghazaryan V, Dempsey W, Nayak SU, Dodd LE, Beigel JH, Kalil AC; ACTT-4 Study Group. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. *Lancet Respir Med*. 2022 Sep;10(9):888-899. [https://doi.org/10.1016/S2213-2600\(22\)00088-1](https://doi.org/10.1016/S2213-2600(22)00088-1) Epub 2022 May 23. PMID: 35617986; PMCID: PMC9126560

Calder T, Tong T, Hu DJ, Kim JH, Kotloff KL, Koup RA, Marovich MA, McElrath MJ, Read SW, Robb ML, Renzullo PO, D'Souza MP. Leveraging lessons learned from the COVID-19 pandemic for HIV. *Commun Med (Lond)*. 2022 Aug 29;2:110. <https://doi.org/10.1038/s43856-022-00175-8> eCollection 2022. PMID: 36045906; PMCID: PMC9423691

Matrajt L, Brown ER, Cohen MS, Dimitrov D, Janes H. Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study. *BMC Infect Dis*. 2022 Aug 9;22(1):683. <https://doi.org/10.1186/s12879-022-07639-1> PMID: 35945513; PMCID: PMC9361252

Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdury R, Deming ME, Eaton A, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Archer JI, Crandon S, Zemanek JA, Brown ER, Neuzil KM, Stephens DS, Post DJ, Nayak SU, Suthar MS, Roberts PC, Beigel JH, Montefiori DC; DMID 21-0012 Study Group. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. *Cell Rep Med*. 2022 Jul 19;3(7):100679. <https://doi.org/10.1016/j.xcrim.2022.100679> Epub 2022 Jun 20. PMID: 35798000; PMCID: PMC9212999

Branche AR, Roupheal NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Malkin E, Bethony JM, Walsh EE, Graciaa DS, Samaha H, Sherman AC, Walsh SR, Abate G, Oikonomopoulou Z, El Sahly HM, Martin TCS, Rostad CA, Smith MJ, Ladner BG, Porterfield L, Dunstan M, Wald A, Davis T, Atmar RL, Mulligan MJ, Lyke KE, Posavad CM, Meagher MA, Stephens DS, Neuzil KM, Abebe K, Hill H, Albert J, Lewis TC, Giebeig LA, Eaton A, Netzl A, Wilks SH, Türelı S, Makhene M, Crandon S, Lee M, Nayak SU, Montefiori DC, Makowski M, Smith DJ, Roberts PC, Beigel JH; COVAIL Study Group. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. medRxiv. 2022 Jul 15:2022.07.12.22277336. <https://doi.org/10.1101/2022.07.12.22277336> Preprint. PMID: 35898343; PMCID: PMC9327623

Fintzi J, Bonnett T, Sweeney DA, Huprikar NA, Ganesan A, Frank MG, McLellan SLF, Dodd LE, Tebas P, Mehta AK. Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: Implications for Critical Care Resource Utilization. Clin Infect Dis. 2022 Jul 6;74(12):2209-2217. <https://doi.org/10.1093/cid/ciab712> PMID: 34409989; PMCID: PMC8499739

Fintzi J, Bonnett T, Tebas P, Marconi VC, Levine CB, El Sahly HM, McLellan SLF, Benson CA, Rostad CA, Ganesan A, Huprikar N, Frank MG, Mularski RA, Atmar RL, Park PK, Short WR, Beigel JH, Mehta AK, Sweeney DA. Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. Open Forum Infect Dis. 2022 Apr 27;9(7):ofac219. <https://doi.org/10.1093/ofid/ofac219> eCollection 2022 Jul. PMID: 35818363; PMCID: PMC9129131

Smith ER, Oakley E, He S, Zavala R, Ferguson K, Miller L, Grandner GW, Abejirinde IO, Afshar Y, Ahmadzia H, Aldrovandi G, Akelo V, Tippet Barr BA, Bevilacqua E, Brandt JS, Broutet N, Fernández Buhigas I, Carrillo J, Clifton R, Conry J, Cosmi E, Delgado-López C, Divakar H, Driscoll AJ, Favre G, Flaherman V, Gale C, Gil MM, Godwin C, Gottlieb S, Hernandez Bellolio O, Kara E, Khagayi S, Kim CR, Knight M, Kotloff K, Lanzone A, Le Doare K, Lees C, Litman E, Lokken EM, Laurita Longo V, Magee LA, Martinez-Portilla RJ, McClure E, Metz TD, Money D, Mullins E, Nachega JB, Panchaud A, Playle R, Poon LC, Raiten D, Regan L, Rukundo G, Sanin-Blair J, Temmerman M, Thorson A, Thwin S, Tolosa JE, Townson J, Valencia-Prado M, Visentin S, von Dadelszen P, Adams Waldorf K, Whitehead C, Yang H, Thorlund K, Tielsch JM. Protocol for a sequential, prospective meta-analysis to describe coronavirus disease 2019 (COVID-19) in the pregnancy and postpartum periods. PLoS One. 2022 Jun 16;17(6):e0270150. <https://doi.org/10.1371/journal.pone.0270150> eCollection 2022. PMID: 35709239; PMCID: PMC9202913

Lin DY, Baden LR, El Sahly HM, Essink B, Neuzil KM, Corey L, Miller J; COVE Study Group. Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial. JAMA Netw Open. 2022 Jun 1;5(6):e2215984. <https://doi.org/10.1001/jamanetworkopen.2022.15984> PMID: 35675078; PMCID: PMC9178430

Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, Finkelstein D, Pickrell P, Kirstein J, Yut C, Blair R, Clifford RA, Dunn M, Campbell JD, Montefiori DC, Tomassini JE, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, McPhee R, Pajon R, Das R, Miller JM, Schnyder Ghamloush S; KidCOVE Study Group. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N Engl J Med. 2022 May 26;386(21):2011-2023. <https://doi.org/10.1056/NEJMoa2203315> Epub 2022 May 11. PMID: 35544369; PMCID: PMC9127699

Cohen TS, Kelly EJ, Nylander S, Bansal H, Jepson BM, Bhuyan P, Sobieszczyk ME, Falsey AR. Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination. Sci Rep. 2022 May 13;12(1):7961. <https://doi.org/10.1038/s41598-022-11623-9> PMID: 35562373; PMCID: PMC9103599

Munoz FM, Beigi RH, Posavad CM, Richardson BA, Chu HY, Bok K, Campbell J, Cardemil C, DeFranco E, Frenck RW, Makhene M, Piper JM, Sheffield J, Miller A, Neuzil KM. Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol. *BMC Pregnancy Childbirth*. 2022 May 12;22(1):402. <https://doi.org/10.1186/s12884-022-04500-w> PMID: 35550037; PMCID: PMC9096328

Anderson E, Jackson L, Roupheal N, Widge A, Montefiori D, Doria-Rose N, Suthar M, Cohen K, O'Connell S, Makowski M, Makhene M, Buchanan W, Spearman P, Creech CB, O'Dell S, Schmidt S, Leav B, Bennett H, Pajon R, Posavad C, Hural J, Beigel J, Albert J, Abebe K, Eaton A, Rostad C, Rebolledo P, Kamidani S, Graciaa D, Coler R, McDermott A, Ledgerwood J, Mascola J, DeRosa S, Neuzil K, McElrath MJ, Roberts P. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine "An Interim Analysis. *Res Sq*. 2022 May 3:rs.3.rs-1222037. <https://doi.org/10.21203/rs.3.rs-1222037/v1> Preprint. PMID: 35547849; PMCID: PMC9094107

Bartsch YC, Tong X, Kang J, Avendaño MJ, Serrano EF, García-Salum T, Pardo-Roa C, Riquelme A, Cai Y, Renzi I, Stewart-Jones G, Chen B, Medina RA, Alter G. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. *Sci Transl Med*. (2022 Apr 27);14(642):eabn9243. <https://doi.org/10.1126/scitranslmed.abn9243> PMID: 35289637; PMCID: PMC8995028

Paules CI, Gallagher SK, Rapaka RR, Davey RT, Doernberg SB, Grossberg R, Hynes NA, Ponce PO, Short WR, Voell J, Wang J, Yang OO, Wolfe CR, Lye DC, Dodd LE, Benson CA. Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data. *Clin Infect Dis*. 2022 Apr 9;74(7):1260-1264. <https://doi.org/10.1093/cid/ciab695> PMID: 34379740; PMCID: PMC8436376

Pajon R, Paila YD, Girard B, Dixon G, Kacena K, Baden LR, El Sahly HM, Essink B, Mullane KM, Frank I, Denhan D, Kerwin E, Zhao X, Ding B, Deng W, Tomassini JE, Zhou H, Leav B, Schödel F; COVE Trial Consortium. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. *Nat Med*. 2022 Apr;28(4):823-830. <https://doi.org/10.1038/s41591-022-01679-5> Epub 2022 Feb 10. PMID: 35145311; PMCID: PMC9018421

Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, Tong J, Eaton A, Maglinao M, Tang H, Manning KE, Edara VV, Lai L, Ellis M, Moore KM, Floyd K, Foster SL, Posavad CM, Atmar RL, Lyke KE, Zhou T, Wang L, Zhang Y, Gaudinski MR, Black WP, Gordon I, Guech M, Ledgerwood JE, Misasi JN, Widge A, Sullivan NJ, Roberts PC, Beigel JH, Korber B, Baden LR, El Sahly H, Chalkias S, Zhou H, Feng J, Girard B, Das R, Aunins A, Edwards DK, Suthar MS, Mascola JR, Montefiori DC. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. *N Engl J Med*. 2022 Mar 17;386(11):1088-1091. <https://doi.org/10.1056/NEJMc2119912> Epub 2022 Jan 26. PMID: 35081298; PMCID: PMC8809504

Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH; DMID 21-0012 Study Group. Homologous and Heterologous Covid-19 Booster Vaccinations. *N Engl J Med*. 2022 Mar 17;386(11):1046-1057. <https://doi.org/10.1056/NEJMoa2116414> Epub 2022 Jan 26. PMID: 35081293; PMCID: PMC8820244

Chalkias S, Schwartz H, Nestorova B, Feng J, Chang Y, Zhou H, Dutko FJ, Edwards DK, Montefiori D, Pajon R, Leav B, Miller JM, Das R. Safety and Immunogenicity of a 100 µg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). *medRxiv*. 2022 Mar 7:2022.03.04.22271830. <https://doi.org/10.1101/2022.03.04.22271830> Preprint. PMID: 35291289; PMCID: PMC8923111



Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, Vingerhoets J, Custers J, Scheper G, Robb ML, Treanor J, Ryser MF, Barouch DH, Swann E, Marovich MA, Neuzil KM, Corey L, Stoddard J, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. *N Engl J Med*. 2022 Mar 3;386(9):847-860. <https://doi.org/10.1056/NEJMoa2117608> Epub 2022 Feb 9. PMID: 35139271; PMCID: PMC8849184

Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenber RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301 Study Group. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. *N Engl J Med*. 2022 Feb 10;386(6):531-543. <https://doi.org/10.1056/NEJMoa2116185> Epub 2021 Dec 15. PMID: 34910859; PMCID: PMC8693692

Kaplonek P, Fischinger S, Cizmeci D, Bartsch YC, Kang J, Burke JS, Shin SA, Dayal D, Martin P, Mann C, Amanat F, Julg B, Nilles EJ, Musk ER, Menon AS, Krammer F, Saphire EO, Andrea Carfi, Alter G. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. *Immunity*. (2022 Feb 8);55(2):355-365.e4. <https://doi.org/10.1016/j.immuni.2022.01.001> PMID: 35090580; PMCID: PMC873321

O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. *JAMA*. 2022 Feb 1;327(5):432-441. <https://doi.org/10.1001/jama.2021.24939> PMID: 35029629; PMCID: PMC8808333

Girard B, Tomassini JE, Deng W, Maglinao M, Zhou H, Figueroa A, Ghamloush SS, Montefiori DC, Das R, Pajon R. mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children. *medRxiv*. 2022 Jan 25:2022.01.24.22269666. <https://doi.org/10.1101/2022.01.24.22269666> Preprint. PMID: 35118475; PMCID: PMC8811908

Jochum S, Kirste I, Hortsch S, Grunert VP, Legault H, Eichenlaub U, Kashlan B, Pajon R. Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial. *Front Immunol*. 2022 Jan 19;12:798117. <https://doi.org/10.3389/fimmu.2021.798117> eCollection 2021. PMID: 35126362; PMCID: PMC8807632

Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Huynh C, Miller J, El Sahly HM, Baden LR, Baron M, De La Cruz L, Gay C, Kalams S, Kelley CF, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA; Immune Assays Team§; Moderna, Inc. Team§; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team§; United States Government (USG)/CoVPN Biostatistics Team§. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science*. 2022 Jan 7;375(6576):43-50. <https://doi.org/10.1126/science.abm3425> Epub 2021 Nov 23. PMID: 34812653; PMCID: PMC9017870

Stankiewicz Karita HC, Dong TQ, Johnston C, Neuzil KM, Paasche-Orlow MK, Kissinger PJ, Bershteyn A, Thorpe LE, Deming M, Kottkamp A, Laufer M, Landovitz RJ, Luk A, Hoffman R, Roychoudhury P, Margaret CA, Greninger AL, Huang ML, Jerome KR, Wener M, Celum C, Chu HY, Baeten JM, Wald A, Barnabas RV, Brown ER. Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. *JAMA Netw Open*. 2022 Jan 4;5(1):e2142796.

<https://doi.org/10.1001/jamanetworkopen.2021.42796> PMID: 35006245; PMCID: PMC8749477

Baden LR, El Sahly HM, Essink B, Follmann D, Neuzil KM, August A, Clouting H, Fortier G, Deng W, Han S, Zhao X, Leav B, Talarico C, Girard B, Paila YD, Tomassini JE, Schödel F, Pajon R, Zhou H, Das R, Miller J. Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. *N Engl J Med*. 2021 Dec 23;385(26):2485-2487.

<https://doi.org/10.1056/NEJMc2115597> Epub 2021 Nov 3. PMID: 34731553; PMCID: PMC8609569

Strohmeier S, Amanat F, Zhu X, McMahon M, Deming ME, Pasetti MF, Neuzil KM, Wilson IA, Krammer F. A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. *mBio*. 2021 Dec 21;12(6):e0224121. <https://doi.org/10.1128/mBio.02241-21> Epub 2021 Nov 23. PMID: 34809451; PMCID: PMC8609353

Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, McEvoy C, DeJesus E, Hassman M, Little SJ, Pahud BA, Durbin A, Pickrell P, Daar ES, Bush L, Solis J, Carr QO, Oyedele T, Buchbinder S, Cowden J, Vargas SL, Guerreros Benavides A, Call R, Keefer MC, Kirkpatrick BD, Pullman J, Tong T, Brewinski Isaacs M, Benkeser D, Janes HE, Nason MC, Green JA, Kelly EJ, Maaske J, Mueller N, Shoemaker K, Takas T, Marshall RP, Pangalos MN, Villafana T, Gonzalez-Lopez A; AstraZeneca AZD1222 Clinical Study Group. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. *N Engl J Med*. 2021 Dec 16;385(25):2348-2360. <https://doi.org/10.1056/NEJMoa2105290> Epub 2021 Sep 29. PMID: 34587382; PMCID: PMC8522798

Huang Y, Borisov O, Kee JJ, Carpp LN, Wrin T, Cai S, Sarzotti-Kelsoe M, McDanal C, Eaton A, Pajon R, Hural J, Posavad CM, Gill K, Karuna S, Corey L, McElrath MJ, Gilbert PB, Petropoulos CJ, Montefiori DC. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. *Sci Rep*. 2021 Dec 14;11(1):23921. <https://doi.org/10.1038/s41598-021-03154-6> PMID: 34907214; PMCID: PMC8671391

Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, Wolfe CR, Ruiz-Palacios GM, Kline S, Regalado Pineda J, Luetkemeyer AF, Harkins MS, Jackson PEH, Iovine NM, Tapson VF, Oh MD, Whitaker JA, Mularski RA, Paules CI, Ince D, Takasaki J, Sweeney DA, Sandkovsky U, Wyles DL, Hohmann E, Grimes KA, Grossberg R, Laguio-Vila M, Lambert AA, Lopez de Castilla D, Kim E, Larson L, Wan CR, Traenkner JJ, Ponce PO, Patterson JE, Goepfert PA, Sofarelli TA, Mocherla S, Ko ER, Ponce de Leon A, Doernberg SB, Atmar RL, Maves RC, Dangond F, Ferreira J, Green M, Makowski M, Bonnett T, Beresnev T, Ghazaryan V, Dempsey W, Nayak SU, Dodd L, Tomashek KM, Beigel JH; ACTT-3 study group members. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Respir Med*. 2021 Dec;9(12):1365-1376. [https://doi.org/10.1016/S2213-2600\(21\)00384-2](https://doi.org/10.1016/S2213-2600(21)00384-2) Epub 2021 Oct 18. PMID: 34672949; PMCID: PMC8523116

Choi A, Koch M, Wu K, Dixon G, Oestreicher J, Legault H, Stewart-Jones GBE, Colpitts T, Pajon R, Bennett H, Carfi A, Edwards DK. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants. *J Virol*. 2021 Nov 9;95(23):e0131321. <https://doi.org/10.1128/JVI.01313-21> Epub 2021 Sep 22. PMID: 34549975; PMCID: PMC8577347

El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med*. 2021 Nov 4;385(19):1774-1785. <https://doi.org/10.1056/NEJMoa2113017> Epub 2021 Sep 22. PMID: 34551225; PMCID: PMC8482810

Mateus J, Dan JM, Zhang Z, Rydyznski Moderbacher C, Lammers M, Goodwin B, Sette A, Crotty S, Weiskopf D. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. *Science*. 2021 Oct 22;374(6566):eabj9853. <https://doi.org/10.1126/science.abj9853> Epub 2021 Oct 22. PMID: 34519540; PMCID: PMC8542617

Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B, Jackson L, Leav B, Ledgerwood JE, Luke CJ, Makowski M, Nason MC, Roberts PC, Roederer M, Rebolledo PA, Rostad CA, Roupheal NG, Shi W, Wang L, Widge AT, Yang ES; mRNA-1273 Study Group; Beigel JH, Graham BS, Mascola JR, Suthar MS, McDermott AB, Doria-Rose NA, Arega J, Beigel JH, Buchanan W, Elsafty M, Hoang B, Lampléy R, Kolhekar A, Koo H, Luke C, Makhene M, Nayak S, Pikaart-Tautges R, Roberts PC, Russell J, Sindall E, Albert J, Kunwar P, Makowski M, Anderson EJ, Bechnak A, Bower M, Camacho-Gonzalez AF, Collins M, Drobeniuc A, Edara VV, Edupuganti S, Floyd K, Gibson T, Ackerley CMG, Johnson B, Kamidani S, Kao C, Kelley C, Lai L, Macenczak H, McCullough MP, Peters E, Phadke VK, Rebolledo PA, Rostad CA, Roupheal N, Scherer E, Sherman A, Stephens K, Suthar MS, Teherani M, Traenkner J, Winston J, Yildirim I, Barr L, Benoit J, Carste B, Choe J, Dunstan M, Erolin R, Ffitch J, Fields C, Jackson LA, Kiniry E, Lasicka S, Lee S, Nguyen M, Pimienta S, Suyehira J, Witte M, Bennett H, Altaras NE, Carfi A, Hurley M, Leav B, Pajon R, Sun W, Zaks T, Coler RN, Larsen SE, Neuzil KM, Lindesmith LC, Martinez DR, Munt J, Mallory M, Edwards C, Baric RS, Berkowitz NM, Boritz EA, Carlton K, Corbett KS, Costner P, Creanga A, Doria-Rose NA, Douek DC, Flach B, Gaudinski M, Gordon I, Graham BS, Holman L, Ledgerwood JE, Leung K, Lin BC, Louder MK, Mascola JR, McDermott AB, Morabito KM, Novik L, O'Connell S, O'Dell S, Padilla M, Pegu A, Schmidt SD, Shi W, Swanson PA 2nd, Talana CA, Wang L, Widge AT, Yang ES, Zhang Y, Chappell JD, Denison MR, Hughes T, Lu X, Pruijssers AJ, Stevens LJ, Posavad CM, Gale M Jr, Menachery V, Shi PY. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. *Science*. 2021 Sep 17;373(6561):1372-1377. <https://doi.org/10.1126/science.abj4176> Epub 2021 Aug 13. PMID: 34385356; PMCID: PMC8691522

Rathe JA, Hemann EA, Eggenberger J, Li Z, Knoll ML, Stokes C, Hsiang TY, Netland J, Takehara KK, Pepper M, Gale M. Corrigendum to: SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing. *J Infect Dis*. 2021 Aug 16;224(4):741-745. <https://doi.org/10.1093/infdis/jiab198> PMID: 34250540; PMCID: PMC8344695

Follmann D, Fintzi J, Fay MP, Janes HE, Baden LR, El Sahly HM, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, Cohen MS, Corey L, Gilbert PB, Neuzil KM. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. *Ann Intern Med*. 2021 Aug;174(8):1118-1125. <https://doi.org/10.7326/M20-8149> Epub 2021 Apr 13. PMID: 33844575; PMCID: PMC8099035

Deming ME, Lyke KE A 'Mix and Match' Approach to SARS-CoV-2 Vaccination. *Nature Medicine*. 2021 Jul 26, <https://doi.org/10.1038/s41591-021-01463-x> PMID: 34312555

Colombo CJ, Colombo RE, Maves RC, Branche AR, Cohen SH, Elie MC, George SL, Jang HJ, Kalil AC, Lindholm DA, Mularski RA, Ortiz JR, Tapson V, Liang CJ. Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort. *Crit Care Explor*. 2021 Jul 13;3(7):e0474. <https://doi.org/10.1097/CCE.0000000000000474> eCollection 2021 Jul. PMID: 34278310; PMCID: PMC8280088

Cohen MS, Nirula A, Mulligan MJ, Novak RM, Marovich M, Yen C, Stemer A, Mayer SM, Wohl D, Brengle B, Montague BT, Frank I, McCulloh RJ, Fichtenbaum CJ, Lipson B, Gabra N, Ramirez JA, Thai C, Chege W, Gomez Lorenzo MM, Sista N, Fariori J, Clement ME, Brown ER, Custer KL, Van Naarden J, Adams AC, Schade AE, Dabora MC, Knorr J, Price KL, Sabo J, Tuttle JL, Klekotka P, Shen L, Skovronsky DM; BLAZE-2 Investigators. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. *JAMA*. 2021 Jul 6;326(1):46-55.

<https://doi.org/10.1001/jama.2021.8828> PMID: 34081073; PMCID: PMC8176388

Greaney AJ, Loes AN, Gentles LE, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. *Sci Transl Med*. 2021 Jun 30;13(600):eabi9915. <https://doi.org/10.1126/scitranslmed.abi9915> Epub 2021 Jun 8. PMID: 34103407; PMCID: PMC8369496

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Dougouih M; ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med*. 2021 Jun 10;384(23):2187-2201.

<https://doi.org/10.1056/NEJMoa2101544> Epub 2021 Apr 21. PMID: 33882225; PMCID: PMC8220996

Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, O'Dell S, Schmidt SD, Widge AT, Edara VV, Anderson EJ, Lai L, Floyd K, Roupheal NG, Zarnitsyna V, Roberts PC, Makhene M, Buchanan W, Luke CJ, Beigel JH, Jackson LA, Neuzil KM, Bennett H, Leav B, Albert J, Kunwar P; mRNA-1273 Study Group. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *N Engl J Med*. 2021 Jun 10;384(23):2259-2261.

<https://doi.org/10.1056/NEJMc2103916> Epub 2021 Apr 6. PMID: 33822494; PMCID: PMC8524784

Mantus G, Nyhoff LE, Kauffman RC, Edara VV, Lai L, Floyd K, Shi PY, Menachery VD, Edupuganti S, Scherer EM, Kay A, McNair N, Anderson EJ, Roupheal N, Ahmed R, Suthar MS, Wrammert J. Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding Domain. *J Immunol*. 2021 Jun 1;206(11):2605-2613.

<https://doi.org/10.4049/jimmunol.2001420> Epub 2021 May 5. PMID: 33952616; PMCID: PMC8482837

Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. *JAMA*. 2021 May 11;325(18):1896-1898. <https://doi.org/10.1001/jama.2021.4388> PMID: 33739374; PMCID: PMC7980146

Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, Mantus G, Nyhoff LE, Adelman MW, Fineman R, Patel S, Byram R, Gomes DN, Michael G, Abdullahi H, Beydoun N, Panganiban B, McNair N, Hellmeister K, Pitts J, Winters J, Kleinhenz J, Usher J, O'Keefe JB, Piantadosi A, Waggoner JJ, Babiker A, Stephens DS, Anderson EJ, Edupuganti S, Roupheal N, Ahmed R, Wrammert J, Suthar MS. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. *Cell Host Microbe*. 2021 Apr 14;29(4):516-521.e3. <https://doi.org/10.1016/j.chom.2021.03.009> Epub 2021 Mar 20. PMID: 33798491; PMCID: PMC7980225

Marchiano S, Hsiang TY, Khanna A, Higashi T, Whitmore LS, Bargehr J, Davaapil H, Chang J, Smith E, Ong LP, Colzani M, Reinecke H, Yang X, Pabon L, Sinha S, Najafian B, Sniadecki NJ, Bertero A, Gale M Jr, Murry CE. SARS-CoV-2 Infects Human Pluripotent Stem Cell-Derived Cardiomyocytes, Impairing Electrical and Mechanical Function. *Stem Cell Reports*. 2021 Mar; 16(3): 478–92.

<https://doi.org/10.1016/j.stemcr.2021.02.008> PMID: 33657418; PMCID: PMC7881699

Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Roupshael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med*. 2021 Mar 4;384(9):795-807.

<https://doi.org/10.1056/NEJMoa2031994> Epub 2020 Dec 11. PMID: 33306283; PMCID: PMC7745180

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupshael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Broz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021 Feb 4;384(5):403-416.

<https://doi.org/10.1056/NEJMoa2035389> Epub 2020 Dec 30. PMID: 33378609; PMCID: PMC7787219

Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first?. *Sci Adv*. 2021 Feb 3;7(6):eabf1374. <https://doi.org/10.1126/sciadv.abf1374> Print 2020 Feb. PMID: 33536223; PMCID: PMC8128110

Widge AT, Roupshael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH; mRNA-1273 Study Group. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N Engl J Med*. 2021 Jan 7;384(1):80-82. <https://doi.org/10.1056/NEJMc2032195> Epub 2020 Dec 3. PMID: 33270381; PMCID: PMC7727324

Anderson EJ, Roupshael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA 2nd, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *N Engl J Med*. 2020 Dec 17;383(25):2427-2438. <https://doi.org/10.1056/NEJMoa2028436> Epub 2020 Sep 29. PMID: 32991794; PMCID: PMC7556339

Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E, Roupshael N, Edupuganti S, Shi PY, Menachery VD, Wrammert J, Suthar MS. Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. *Curr Protoc Immunol*. 2020 Dec;131(1):e116.

<https://doi.org/10.1002/cpim.116> PMID: 33215858; PMCID: PMC7864545

Jackson LA, Anderson EJ, Roupshael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med*. 2020 Nov 12;383(20):1920-1931. <https://doi.org/10.1056/NEJMoa2022483> Epub 2020 Jul 14. PMID: 32663912; PMCID: PMC7377258

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med.* 2020 Nov 5;383(19):1813-1826. <https://doi.org/10.1056/NEJMoa2007764> Epub 2020 Oct 8. PMID: 32445440; PMCID: PMC7262788

Stephens DS, McElrath MJ. COVID-19 and the Path to Immunity. *JAMA.* 2020 Oct 6;324(13):1279. <https://doi.org/10.1001/jama.2020.16656> PMID: 32915201

Dou Y, Fatemi S, Darvas M, Gale M, Jr, Ladiges W. A Geroscience Approach to Preventing Pathologic Consequences of COVID-19. *J Interferon Cytokine Res.* 2020 Sep;40(9):433-437. <https://doi.org/10.1089/jir.2020.29018.dou> Epub 2020 Aug 13. PMID: 32790488; PMCID: PMC7645979

Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, Vanderheiden A, Nyhoff L, Davis CW, Adekunle O, Affer M, Sherman M, Reynolds S, Verkerke HP, Alter DN, Guarner J, Bryksin J, Horwath MC, Arthur CM, Saakadze N, Smith GH, Edupuganti S, Scherer EM, Hellmeister K, Cheng A, Morales JA, Neish AS, Stowell SR, Frank F, Ortlund E, Anderson EJ, Menachery VD, Roupheal N, Mehta AK, Stephens DS, Ahmed R, Roback JD, Wrammert J. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. *Cell Rep Med.* 2020 Jun 23;1(3):100040. <https://doi.org/10.1016/j.xcrm.2020.100040> Epub 2020 Jun 8. PMID: 32835303; PMCID: PMC7276302